I've been advised that it would be helpful for any current Pagaclone test
participants or any stutter who would like to participate in the testing of
Pagaclone to write (or preferably fax) the CDO of Endo Pharmaceutical ...
I'm providing the address below for anyone who believes they have or may
benefit from Pagaclone to make their voices heard in this decision. Once
the decision is made to shut down the project, it will be much harder to
restart the program. At this point I would suggest faxing a letter and
mailing a copy to the address below. Contact me if I can answer any
questions. Thanks. Jim.
David P. Holveck, CEO
100 Endo Boulevard
Chadds Ford, PA 19317
United States - Map
Monday, September 06, 2010
Should Endo continue trial?
James Dunlap asks me to publish his request for a continuation of the Pagoclone trial. I am staying out of this. I am not sure a continuation makes sense on their part. I guess the key is whether there are subgroups who benefit and they can identify them. And with benefit, I mean beyond placebo, measurement bias, and fluke correlation. Overall, I am rather pessimistic.
by Tom Weidig